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Dialytic nutrition: Provision of amino acids in dialysate during hemo-
dialysis. Maintenance hemodialysis (MHD) patients are frequently ma!-
nourished, a condition associated with high morbidity and mortality.
Amino acid (AA) losses in dialysate may enhance protein malnutrition in
patients with low food intake. We studied the possibility of providing AA
in dialysate during MHD to either prevent AA losses or as a nutritional
supplement. Six clinically stable men were studied during three hemodi-
alysis treatments. The first treatment was performed using the usual
dialysate (OXAA). The two other treatments were performed using a
dialysate containing an amount of AA equal to normal plasma AA
concentrations (1XAA) or to three times the normal plasma AA concen-
trations (3XAA). During the OXAA treatment, the total AA losses were
10.0 0.9 (sEM) grams (g) and the total AA concentrations in plasma
decreased by 49 4%. During the 1XAA treatment, the total AA balance
was +0.8 1.8 g and there was no significant change in the postdialysis
plasma total AA. With the 3XAA treatment, the patients gained 36.9
4.1 g of AA during the hemodialysis treatment and the plasma total AA
levels increased by 45 9%. No side effects were observed. These findings
indicate that it may be feasible to provide AA supplements to MilD
patients by adding AA to hemodialysate.
It is well recognized that there is a high prevalence of protein-
calorie malnutrition in maintenance hemodialysis (MHD) pa-
tients [1]. Malnutrition, particularly as indicated by low serum
albumin levels or reduced dietary protein intake, is of great
concern because it is associated with a high incidence of morbidity
and mortality [2, 3]. Although several factors contribute to
malnutrition in MHD patients, decreased ingestion of food due to
anorexia, intercurrent illnesses, and/or socio-econornic conditions
are major causes of this disorder [1, 2, 4]. Losses of amino acids
into hemodialysate may contribute to protein malnutrition, par-
ticularly in patients with low nutrient intakes. Attempts to in-
crease the intake of foods by counseling the patient, increasing the
dialysis dose or providing food supplements often do not raise the
dietary nutrient intake to the desired levels. Studies of intradia-
lytic parenteral nutrition (IDPN) suggest that it may improve
nutritional status and clinical outcome [5—7], although large scale,
prospective, randomized clinical studies of this treatment have not
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been carried out. However, IDPN is expensive, and, in the United
States, the Health Care Financing Administration has severely
restricted the medical conditions for which IDPN is reimbursable
[8]. Since the molecular weights of amino acids are sufficiently
small to allow substantial clearances by dialyzer membranes, we
examined whether adding amino acids to hemodialysate could
either eradicate the net losses of amino acids or actually provide
a nutritional supplement of these amino acids during hemodialy-
sis. The results of this study indicate that the addition of amino
acids to hemodialysate can be used both to prevent losses and to
provide amino acids to the patient.
METHODS
Patient characteristics
Six male MHD patients were studied. Their mean age was 50.9
years (range, 30.6 to 61.6 years), duration of hemodialysis was 50
months (12 to 160 months), height was 174 3.9 (sM) cm, and
body wt was 75.8 5.4 kg. The relative body wt [9] was 92.7
5.2%; three patients had a relative body wt less than 90% [9].
Body mass index was 25.0 1.1 kg/rn2, and serum albumin was
4.1 0.1 g/dl (range, 3.8 to 4.2 g/dl). The patients underwent
hemodialysis three times weekly for three hours (in 4 patients) or
four hours (in 2 patients) using a single-pass technique; reused
polysulfone dialyzers and bicarbonate buffered dialysate were
employed. End-stage renal disease was caused by IgA nephropa-
thy in two patients and by malignant hypertension, diabetic
nephropathy, polycystic kidney disease and unknown factors in
one patient each. Two patients were receiving antihypertensive
medicines (nifedipine alone in one patient or combined with
minoxidil and clonidine in the other). All received phosphate
binders. Five patients were routinely given erythropoietin injec-
tions, and all were receiving injections of 1,25-dihydroxycholecal-
ciferol. No patient had received glucocorticoid therapy during the
study or for at least three months before the study.
Experimental design
Each patient was studied during three hemodialysis treatments
that were separated by at least one week. For a given patient, the
three studies were conducted on the same day of the week. The
day of the week on which the study was performed was Monday
(after a 2—5/6 day interval) in Patient 5, and Wednesday, Thursday
or Friday (after a 1—5/6 day interval) in the other five patients. All
patients were fasted from 10:00 p.m. the night before the study
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until the completion of the blood drawing at the end of hemodi-
alysis the next day. Flemodialyses were prescribed to last for 240
minutes and began between 7:00 and 9:00 a.m. and ended
between 11:00 a.m. and 1:00 p.m. Blood was drawn at the exact
beginning and end of the hemodialysis treatment for measure-
ment of urea and amino acids. The grand mean of the average
urea reduction ratio during the three hemodialyses in each patient
was 70.3 1.0%.
In all patients, blood flow was set at 400 mi/mm and dialysate
flow was maintained at 500 mi/mm. The rate of blood flow and
dialysate inflow was determined by a pump that was periodically
calibrated. The dialysate inflow was measured by a flow meter that
was also calibrated periodically. All hemodialyses were performed
with cellulose triacetate CT 190 G®, 1.9 m2 dialyzers (Baxter
Heaithcare, Deerfield, IL, USA). Dialyzers were not reused in the
study. The standard composition of all dialysates used in the study
was as follows: D-glucose monohydrate 200 mg/dl, sodium 138 to
139 mEq/liter, potassium 1 to 3 mEq/liter, chloride 104 to 106
mEq/liter, bicarbonate 35 mEq/iiter, calcium 2.5 to 3.5 mEq/liter,
magnesium 0.7 to 1.5 mEq/liter. The first hemodialysis treatment
of the study was performed using the patient's usual dialysate,
without any amino acids added (referred to as OXAA). For each
patient, the order of administration of the two hemodialyses with
amino acids added was determined randomly. The composition of
dialysate used with these latter two hemodialyses was identical to
the OXAA hemodialysate with the following exceptions: during
one hemodialysis, the dialysate contained 20 amino acids in
concentrations that were similar to that present in plasma from
normal postabsorptive adults (that is, the plasma amino acid
concentrations after an overnight fast, referred to as 1XAA). The
other hemodialysis was performed with a dialysate that contained
amino acids in concentrations similar to three times normal
postabsorptive plasma values (referred as to 3XAA).
In order to attain these amino acid concentrations in the
delivered dialysate, the 20 amino acids were purchased separately
as a dry powder (Ajinomoto Corporation, Japan) and mixed
together. An amount of 46.4 and 139.2 g of this amino acid
mixture was added to 3.7 liters of the acid dialysate concentrate in
order to attain the 1XAA and 3XAA concentrations, respectively,
in the diluted delivered dialysate. The enriched concentrate was
thoroughly stirred for two hours, filtered and stored at 4°C until
the hemodialysis was performed the next day. A sample from the
enriched acid dialysate concentrate was drawn at the beginning of
the dialysis treatment and cultured for bacteria. During the
dialysis treatment, one volume of the acid concentrate was added
to 34 volumes of water purified by reverse osmosis and to 1.36
volume of bicarbonate solution concentrate by a Baxter 550 single
pass delivery system.
All spent dialysate was collected in the following manner: the
spent dialysate flowed into small 10 liter holding tank. A propor-
tioning pump (Masterfiex®, Cole-Parmer Instrument Co, Niles,
IL, USA) continuously transferred dialysate from the holding
tank into either a 10 liter jug or a large vat. The ratio of the
volume of dialysate transferred to the jug versus the vat was kept
constant at 1 to 18. The jug was packed in ice to reduce bacterial
growth. At the end of hemodialysis, the total volume of dialysate
outflow in the chilled jug and the vat was weighed. The dialysate
in the jug was stirred, and three 30 ml aliquots of spent dialysate
each were taken and quickly frozen at —20°C until analyzed for
amino acids. During dialysis with 1XAA and 3XAA, a 10 ml
aliquot of fresh dialysate was collected at the beginning, midpoint
(120 mm) and end of hemodialysis for amino acid analyses, and
was also stored at —20°C until analyzed.
Blood was collected in heparinized tubes at the exact onset and
termination of hemodialysis. The blood was centrifuged within
five minutes of collection at 1300 x g for 10 minutes. Plasma was
quickly separated and deproteinized by adding 100 pJ of 4.5%
sulfosalicylic acid to 1.0 ml of plasma, mixed with a vortex mixer,
and centrifuged at 4°C for 10 minutes. The supernatant was
pipetted and recentrifuged for 10 minutes at 4°C if flecks of white
precipitate were observed in the solution. The supernatant was
then stored at —20°C until analysis. For each hemodialysis, amino
acids were measured in three specimens of fresh hemodialysate
(with the 1XAA and 3XAA hemodialyses), in triplicate in each
collection of spent dialysate, and in the deproteinized plasma
obtained at the beginning and end of each hemodialysis. Almost
all specimens were analyzed for amino acids within seven days of
collection.
Amino acid measurements were performed with a Beckman
Model 6300 Amino Acid Analyzer (Beckman Instruments, Palo
Alto, CA, USA) using a lithium buffer system. For analyses of the
hemodialysate containing the 1XAA and 3XAA amino acid
concentrations, cysteine, citrulline and ornithine were not mea-
surable because of interferences from the chromatographic peaks
of the large quantities of amino acids added to the dialysate. Urea
in plasma and dialysate was measured by the urease method
(Abbott Laboratories, South Pasadena, CA, USA). For the OXAA
hemodialysis, the amino acid (AA) balance across the dialyzer was
considered to be equal the total amino acids in the spent dialysate
and was calculated as follows:
Total AA in spent dialysate
= spent dialysate AA concentration (mg/mi)
>< spent dialysate volume (ml)
For the hemodialyses (HD) performed with the 1XAA and
3XAA treatments, the quantity of amino acids delivered to the
dialyzer was calculated as follows:
Fresh dialysate AA concentration (mg/mi)
x Fresh dialysate flow (mi/mm) x Duration of HD (mm)
Fresh dialysate flow was calculated as the volume of spent
dialysate (liters) minus total ultrafiltration (liters) divided by the
duration of hemodialysis treatment (minutes). Total ultrafiltrate
was taken as the patient's weight change during the dialysis. It was
assumed that the weight of dialysate or the weight change of the
patient was equal to the liters of dialysate or of ultrafiltrate.
The amino acid balance with the 1XAA and 3XAA hemodial-
yses was calculated as follows:
Statistical analyses
AA balance across dialyzer =
Total AA delivered to diaiyzer
minus total AA in spent dialysate
The results are expressed as mean SEM (sEM). The individual
amino acid levels and the total essential, total semi-essential, total
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Table 1. Expected and measured amino acid concentrations in fresh hemodialysate used for the 1XAA and 3XAA treatments
Expected
values
nol/liter
Measured values
lxAAb 3XAA'
pmol/liter mg/liter jnnol/liter mg/liter
Total essential amino acids
Histidine 80 91 3C 14 0 248 9 38 1
Isoleucine 60 68 2 9 0 183 5 24 1
Leucine 130 139 6 18 1 379 10 50 1
Lysine 180 210 19 43 4 506 37 104 8
Methionine 30 33 2 5 0 91 5 14 1
Phenylalanine 60 62 2 10 0 178 5 29 1
Threonine 150 159 9 19 1 409 18 49 2
Tryptophan 50 —'
Valine 270 339 22 40 3 825 47 97 6
Total 960 1102 58 158 9 2819 119 405 18
Semi-essential amino acids
Tyrosine 28 28 1 5 0 48 4 9 2
Total nonessential amino acids
Alanine 300 357 39 32 9 877 55 78 5
Arginine 100 114 6 20 2 302 5 53 1
Asparagine 50 18 4 3 1 91 11 9 4
Aspartic acid 15 15 1 2 0 28 4 2 I
Glutamic acid 90 98 5 14 1 241 21 38 3
Glutamine 500 548 20 80 3 1476 20 216 3
Glycine 320 319 10 24 1 929 24 70 2
Proline 200 208 15 23 2 598 33 66 4
Serine 100 110 3 12 1 294 15 31 2
Taurine 55 67 7 8 1 152 12 19 1
Total 1730 1942 124 218 9 4939 99 582 9
Grand Total Amino Acidse 2718 3058 162 382 18 7777 213 995 26
a Expected values for the 1XAA amino acid concentrations
b 1XAA and 3XAA: the fresh dialysate contains one times and three times the normal postabsorptive amino acid concentrations
C Mean SEM of fresh hemodialysate concentrations from six patientsdTryptophanwas not measured
Refers to the sum of total essential, total semi-essential and total nonessential amino acid concentrations in fresh dialysate
nonessential, and the grand total of the amino acid levels in
dialysate and plasma were each averaged for the six hemodialysis
studies carried out with each of the three treatments. The
possibility that the dialysate AA balances or plasma AA concen-
trations with the three separate treatments (that is, OXAA, 1XAA,
3XAA) were significantly different from each other was tested by
multivariate analysis of variance for repeated measures [10]
(SPSS, Chicago, IL, USA). The differences between plasma pre-
and postdialysis AA concentrations were analyzed with the paired
t-test. Linear regression analyses were used to determine the
relationships between the AA balances across the dialyzer and the
AA concentrations in plasma or fresh dialysate, the molecular
weight of the AA, the urea reduction ratio and the quantity of
urea cleared into the dialysate. A P value < 0.05 was considered
to be statistically significant.
RESULTS
The average duration for the 18 hemodialysis treatments was
237 minutes (range 217 to 241 mm). The hemodialyses with the
amino acids in dialysate were well tolerated by all patients. The
bacterial cultures from 12 acid dialysate concentrates containing
the amino acids for the 1XAA and 3XAA treatments demon-
strated no bacterial growth.
The mean amino acid concentrations measured in fresh hemo-
dialysate containing 1XAA and 3XAA are shown in Table 1. The
grand total amino acid concentrations in the fresh dialysate
averaged 3058 162 .tmol/liter and 7777 213 tmol/Iiter with
the IXAA and 3XAA concentrates. In general, the measured
amino acid concentrations in fresh dialysate were similar to the
expected values with both the 1XAA and 3XAA preparations.
The similarity of these amino acid levels to one times or three
times the normal plasma concentrations is even more evident if
the rather substantial range of the normal values for post-
absorptive plasma amino acid concentrations are taken into
consideration. Indeed, the mean of the ratios of the measured to
the expected concentrations for all of the individual amino acids
was 1.06 0.04 and 2.75 0.1 for the 1XAA and 3XAA dialysate
preparations, respectively.
There were several exceptions to these close relationships. The
tyrosine concentrations with the 3XAA dialysate were lower than
expected, probably because tyrosine is rather insoluble in water,
and some tyrosine may have precipitated in the acid concentrate
before it was diluted. Tryptophan was added to the dialysate, but
the tryptophan concentrations in dialysate were not assessed
because of technical difficulties associated with its measurement.
Citrulline and ornithine were not added to the dialysate because
these amino acids are not found in human proteins, are part of the
urea cycle, and are readily synthesized from arginine. Cysteine
was not included in the amino acid preparation because it is
increased in uremic plasma [11] and it is chemically rather
unstable; thus, methionine, which is its metabolic precursor, was
added.
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Essential amino acids"
Histidine
Isoleucine
Leucine
Lysine
Methionine
Phenylalanine
Threonine
Valine
Total
Semi-essential amino
acids
Cysteine5
Tyrosine
Total
Nonessential amino
acids
Alaninc
Arginine
Asparagine
Aspartic acid
Citrulline8
Glutamic acid
Glutamine
Glycine
Ornithine5
Proline
Serinc
Taurine
Total
OXXA' 1XAA' 3XAA"
Grand Total Amino —9953 848d 790 1798
Acids"
Dialysate containing no amino acids (OXAA) or containing about one
time (IXAA) or three times (3XAA) the normal postabsorptive plasma
amino acid concentrations
Tryptophan was not measured
Mean SEM from six men studied with all three hemodialysis
treatment. A minus sign preceeding the mean value indicates that this
quantity of amino acids was, on average, lost from the patients; the
absence of a minus sign before the mean value indicates that this quantity
of amino acids, on average, was gained by the patients
"Different from 0 (P < 0.05)
P < 0.005 for difference in AA balance between OXAA and IXAA
treatments
P < 0.02 for difference in AA balance between 3XAA and the OXAA
and 1XAA data
gysteine, citrulline and ornithine, that were not added in dialysate (see
text) were not measured in IXAA and 3XAA dialysate because of the
interferences of the added amino acid peaks on the ehromatograms
h Refers to the sum of total essential, total semi-essential and total
nonessential amino acid balances
The amino acid balances across the hemodialyzers during
treatment with the OXAA, 1XAA and 3XAA dialysate concentra-
tions are shown in Table 2. When no amino acids were added to
hemodialysate, there were statistically significant losses of all
individual amino acids as well as total essential, total semi-
essential, total nonessential and the grand total of amino acids.
The total amino acid losses with the OXAA dialysis were 9,953
848 mg. As has been reported previously [12], the mean losses into
dialysate of individual amino acids were highly correlated with the
average predialysis plasma concentrations of the respective amino
Predialysis mean concentration of individual
plasma amino acids, pmol/Iiter
acids (r = 0.88, Fig. 1), but not with the molecular weights of the
amino acids. No correlation was observed between the total
amino acid losses during the OXAA hemodialysis and either the
urea reduction ratio or the urea content in the spent dialysate.
During hemodialysis with the IXAA concentrations, the losses
of individual amino acids, except for arginine, as well as the losses
of total essential (+ 647 861 mg), total nonessential (+59 977
mg) and the grand total amino acids (+ 790 1,798 mg) were not
significantly different from zero (Table 2). There were substantial
individual variations in the grand total amino acid balances among
the six patients, from —5.8 to +7.4 g. The balances for several
individual amino acids and also for total essential and total
nonessential amino acids varied substantially (see variances for
the balances with the 1XAA treatment that are listed in Table 2).
The grand total amino acid balances in the six patients did not
correlate with either their grand total amino acid concentrations
in the fresh 1XAA dialysate or their grand total predialysis amino
acid concentrations in plasma (data not shown).
With the 3XAA dialysate, there was a statistically significant
uptake of all of the individual amino acids that were added to the
fresh dialysate, except for asparagine and aspartic acid. There was
also a large and highly significant uptake of the total essential
(16,516 1,856 mg), total nonessential (19,972 2,441 mg) antI
total amino acids (36,879 4,137 mg; Table 2). For each
individual AA and for total essential AA, total nonessential AA
and the grand total of AA, there were significant differences in the
amino acid balance among the three hemodialysis treatments,
except for the aspartic acid and asparagine balances (Table 2).
Balances for the amino acids were significantly more positive with
the 3XAA dialysate as compared to the 1XAA and OXAA
dialysates. Also, the amino acid balances with the I XAA dialysate
were often significantly more positive as compared to the OXAA
dialysate (Table 2).
There was a highly significant correlation between the mean
uptake of individual amino acids during hemodialysis with the
3XAA hemodialysate and the average concentrations of the
individual amino acids in the fresh dialysate (Fig. 2). The mean
Table 2. Amino acid balance during hemodialysis treatments with
dialysate containing OXAA, 1XAA and 3XAA
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Fig. 1. Relationship between the mean predialysis plasma concentra-
tions of individual amino acids (LmoI/liter) and the mean losses of
84 37C 391 78 individual amino acids into dialysate (mg/hemodialysis treatment). Each
symbol represents the mean predialysis plasma and total dialysate content
for an individual amino acid from six maintenance hemodialysis patients.
Data were obtained from patients who had been fasted from the previous
evening until the end of the hemodialysis treatment. No amino acids were
added to the fresh dialysate entering the dialyzer. y 3.2x + 30.5; r
0.88; P < 0.001.
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Individual AA in fresh dialysate, imoI/Iiter
Fig. 2. Relationship between the mean individual amino acid concentra-
tions in fresh dialysate (mol/liter of dialysate) and the mean balance for
individual amino acids (mg/hemodialysis treatment) during the course of
a four-hour hemodialysis treatment. Hemodialysis was performed using
fresh dialysate that contained amino acids in approximately three times
the postabsorptive plasma amino acid concentrations of normal adults
(3XAA). Each symbol represents the mean dialysate concentration and
balance for an individual amino acid from six maintenance hemodialysis
patients. Patients were fasted from 10 p.m. the night before the study until
the end of the hemodialysis treatment on the study day. y = 4.lx + 245;
r = 0.91.
uptake of individual amino acids also was correlated with the
predialysis individual plasma amino acid concentrations (r = 0.92,
P < 0.0001). This latter relationship may largely reflect the fact
that the predialysis plasma concentrations of individual amino
acids were highly correlated with the amino acid concentrations in
the fresh 3XAA dialysate. Indeed, the amino acid concentrations
in the 3XAA hemodialysate were patterned after the postabsorp-
tive plasma amino acid levels of normal adults, which are not
markedly different from the postabsorptive plasma amino acid
concentrations of MHD patients. No correlation was found
between the amino acid balances and the molecular weights of
individual amino acids. Also, the correlation coefficients for
relationship between the total amino acid balance and the predi-
alysis plasma grand total amino acid concentrations, the urea
reduction ratio and the amount of urea nitrogen removal by the
hemodialysis (g) were respectively 0.60, 0.57 and —0.69. These
correlations were not statistically significant, possibly because only
six patients were evaluated.
The plasma amino acid concentrations at the onset and termi-
nation of the three hemodialyses and the percent changes in these
values are shown in Table 3. The concentrations of essential AA,
semi-essential AA, nonessential AA and total AA in plasma at the
beginning of the three treatments were not statistically different
according to the multivariate analysis of variance. With the OXAA
treatment, all individual amino acid concentrations, as well as
total essential, total semi-essential and total nonessential amino
acids, decreased significantly, with the exception of aspartic acid.
The plasma grand total amino acids also fell significantly, by
1473 148 imol/liter (—49 4%, P < 0.03). With the 1XAA
hemodialysis, there were no significant changes in the plasma
concentrations of total essential or nonessential amino acids, the
grand total of amino acids or the individual amino acids, except
for a decrease in isoleucine, methionine, tyrosine, aspartic acid,
cysteine and citrulline (these latter two amino acids were not
added to the dialysate) and total semi-essential AA (Table 3).
In contrast, during the 3XAA hemodialysis, there were statis-
tically significant increases in the plasma concentrations of total
essential and nonessential amino acids, the grand total of amino
acids and most individuals amino acids (Table 3). The increase in
the plasma grand total amino acid concentrations with the 3XAA
dialysate averaged 1121 138 1.tmol/liter(+45 9%,P <0.001).
The plasma amino acid concentrations that did not increase were
often the ones that were not added to the hemodialysate (that is,
cysteine, citrulline and ornithine) or in which the dialysate con-
centrations tended to be lower than the targeted dialysate con-
centration for that amino acid (that is, tyrosine, asparagine and
aspartic acid with the 3XAA dialysate (Table 1)). Also, the
increase in plasma alanine (P = 0.069) did not reach statistical
significance.
The magnitude of the increases in the mean concentrations of
individual plasma amino acids during hemodialysis with the
3XAA dialysate were correlated with the amino acid concentra-
tions in the fresh dialysate (r = 0.78, P < 0.001), with the balance
of the respective amino acids across the dialyzer (r = 0.70, P <
0.001) and with the predialysis plasma concentrations of individ-
ual amino acids (r = 0.92, P < 0.0001). The postdialysis plasma
levels of individual amino acids with the 3XAA hemodialysis were
also correlated with the predialysis plasma amino acid concentra-
tions (y = 1.4x + 5; r = 0.95,P < 0.0001). Therefore, one may be
able to predict the postdialysis amino acid concentrations pre-
cisely from either the quantity of amino acids added to the
hemodialysate or from the quantities taken up during the hemo-
dialysis procedure.
Thus, the magnitude of the change in plasma total essential and
total nonessential amino acid concentrations, the grand total
amino acid levels and many individual amino acid concentrations
were significantly different according to the dialysate employed.
These changes were frequently significantly more positive with the
3XAA dialysate as compared to the IXAA and OXAA dialysate
and were often more positive with the 1XAA dialysate as com-
pared to the OXAA dialysate (Table 3). As expected, the mean
postabsorptive plasma amino acid concentrations at the onset of
the three different hemodialyses were similar. In contrast, the
postdialysis plasma amino acid levels varied greatly according to
the amino acids levels in the dialysate. The postdialysis plasma
amino acid levels with the 1XAA hemodialysis were essentially
unchanged from the postabsorptive predialysis plasma values,
whereas the postdialysis plasma amino acid concentrations with
the 3XAA treatment were about one and one-half times as great
as with the 1XAA hemodialysis (P < 0.00 1) and were almost three
times as great as with the OXAA treatment (P = 0.001; Table 3).
DISCUSSION
The results of this study indicate that the addition of amino
acids to hemodialysate may prevent amino acid losses during
hemodialysis treatment and, if provided in sufficient quantities,
may provide nourishment to the patient. Six men who were
postabsorptive and who underwent hemodialysis with the high-
flux cellulose triacetate CT19O® dialyzer without amino acids in
the dialysate, sustained losses of total amino acids that averaged
10.0 0.9 g per dialysis. In contrast, when these patients were
treated with hemodialysis in which the dialysate contained amino
acids at concentrations similar to the normal postabsorptive
plasma amino acid levels, there were no significant losses or gains
in total essential, total nonessential or the grand total amino acid
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Table 3. Pre- and postdialysis plasma amino acid values for the three hemodialysis treatments
Blood was obtained at the exact onset and termination of the hemodialysis procedure
b Dialysate containing no amino acids (0XAA) or one times (1XAA) or three times (3XAA) normal postabsorptive plasma amino acid concentrations
Tryptophan was not measured
d Mean SEM
Refers to the sum of total essential, total semi-essential and total nonessential amino acids
t,g,h,, p < 0.0001, < 0.001, < 0.01, < 0.05 differs from the respective predialysis value
j,k P < 0.01, < 0.05 differs from the respective postdialysis OXAA value
" P < 0.001, < 0.01 differs from the respective postdialysis OXAA and 1XAA values
balance (+0.8 1.8 g amino acids per dialysis). When hemodi-
alysis was performed using dialysate that contained three times
the normal postabsorptive plasma amino acid concentrations, the
patients gained an average of 36.9 4.1 g of amino acids per
hemodialysis.
Other researchers have found slightly lower losses of amino
acids in fasting patients when they underwent hemodialysis with
an amino acid free dialysate. Kopple et al reported 6.3 g (range
4.5 to 7.1 g) of amino acid losses during an ii hour dialysis with
the less efficient Kiil dialyzers using a Cuprophan membrane [131.
Wolfson, Jones and Kopple described amino acid losses of 8.1
1.1 g (sEM) with a five hour dialysis with various low flux dialyzers
[12]. Ono, Sasaki and Waki observed amino acid losses of 6.6
0.5 g with a five hour dialysis using a cuprammonium rayon hollow
fiber dialyzer [14]. Gutierrez, Bergstrom and Alvestrand reported
an amino acid removal of 7.9 0.4 g with a Baxter CA17O G or
Gambro GFSP1us 20 dialyzer [151. Ikizler et al described similar
amino acid losses in male patients who ate a small meal and who
underwent dialysis using a low flux cuprophan dialyzer (7.2 0.9
(sEM) g) and a low flux polymethyl methacrylate dialyzer (6.1
0.5 g) [161. When the polysulfone membrane was reused six times,
the free amino acids losses rose to 12.2 1.5 (sEM) g.
In patients who are postprandial, Kopple et al reported 8 to 10 g
of amino acid losses during an 11 hour hemodialysis with the Kiil
dialyzer [13]. The slightly higher amino acid losses with the OXAA
dialysate in the postabsorptive patients in the present study may
reflect the fact that the cellulose triacetate dialyzer is a high flux
membrane (sieving coefficient: 0.55 0.03 for f32-microglohulin).
Indeed, when lkizler et al [16] used a high flux polysulfone
dialyzer with similar parameters of dialysis kinetics (surface area,
blood and dialysate flow rates, duration of dialysis treatment),
only slightly lesser quantities of amino acids were removed, 8.0
0.9 g. The cellulose triacetate dialyzer used in the present study
has a surface area of 1.9 m2 and a pore size of 100 angstroms. The
polysulfone membrane used in the studies of Ikizier et al has a
surface area of 1.8 m2 and a pore size distribution of 60 to 80
angstroms.
The 49 4% decrease in the plasma grand total amino acids
levels during the OXAA hemodialysis in the present study was
somewhat greater then that reported previously (32% decrease in
pinol/liter
OXAA" 1XAAb 3XAA1'
Predialysis PostdialysisChange
% pmol/liter
Change
%
Predialysis Postdialysis Predialysis PostdialysisChange
% panol/liter
Essential amino acidsc
Histidine 79 6' 40 3 —49 2 84 6 77 4' —8 4 83 8 123 11h,m 52 9
Isoleucine 52 6 32 3h —37 4 62 6 49 5 —21 4 59 6 78 7SI 32 5
Leucine 86 10 56 6h —33 6 105 10 99 12 —6 6 100 12 158 l45 63 ii
Lysine
Methionine
195 2731 2 115 13h15 1g —40 2—50 2
192 2229 2 186 l921 2g —l 4—27 4 204 2630 3 302 22g!35 2' 56 1421 8
Phenylalanine
Threonine
52 8
134 11
29 3h
59 4 —42 4—56 2 56 5132 17 51 6k113 11 —10 5—13 4
57 7
120 7
80 6"
200 81,!
58 1769 7
Valine 156 16 78 95 —50 2 229 56 246 33k —17 10 210 33 492 39f 154 29
Total 783 69 423 335 —45 2 887 107 842 82 —4 3 863 91 1468 94 76 12
Semi-essential amino acids
Cysteine
Tyrosine
111 1935 4 14 2"26 4" —76 2—58 5 70 1130 3
28 9
19 45
—58 13
—39 7
115 2634 4 32 9"27 4 —72 7—19 10
Total 146 20 40 5g —72 2 76 15 38 8i,k —51 13 129 28 53 9 —60 6
Nonessential AA
Alanine 389 17 158 9 —42 20 287 54 214 3l —19 9 258 53 345 52" 49 18
Arginine
Asparagine
94 1143 7 43 413 0" —53 3—67 4 110 2244 10 73 629 3 —27 714 19 102 1234 6 148 lOim42 4 64 3542 28
Aspartic acid
Citrulline
20 4
126 25
10 4
42 8h
—41 21
—64 5
12 0
122 23
6 1
66 16
—54 6
—45 8
18 4
170 29
9 2
87 33'
—48 6
—55 6
Glutamic acid 75 4 60 7 —17 13 78 11 91 10" 22 11 68 5 124 81,! 82 8
Glutamine 522 36 305 25 —42 2 513 33 495 33 —2 6 559 40 729 440 31 3
Glycine
Ornithine
293 21
99 12
160 11"
48 5"
—45 4
—51 4
262 28
85 13
253 2355 8 —2 4—29 6 291 25 444 22" 56 10
Proline 273 41 80 7h —69 3 206 27 176 16" —6 16 239 49 306 35"' 38 11
Serine 104 13 58 6h 43 5 84 11 95 18 19 27 84 8 123 15h,m 51 8
Taurine 70 11 34 5 —42 15 73 7 71 6 2 11 86 16 134 5I. 80 26
Total 2076 115 1000 64 —49 5 1786 141 1571 8S —9 5 1842 207 2435 l34"" 39 6
Grand total amino acids" 3005 179 1463 941 —49 4 2750 262 2451 162" —8 5 2834 291 3956 2051! 45 9
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the study of Wolfson et a! [121; 34% by Ono et a! [14]; 23% by
Guttierez et al [151; and 31% by Ikizier et al [161). These rather
minor differences in the fall in plasma amino acids levels may
reflect the fact that in some of the other studies, patients may not
have been fasting [14, 16], postdialysis samples were drawn 15
minutes after the termination of dialysis [161, or less efficient
hemodialyses were employed [13—15]. The fact that our patients
lost slightly more amino acids during the OXAA hemodialysis may
have contributed to the greater decrease in their plasma amino
acid concentrations. Several grams of peptides and protein are
also lost during hemodialysis treatment [13, 16]. Thus, the total
free and bound amino acid losses during hemodialysis are even
greater than are indicated by these studies.
In contrast to these findings, when amino acids were added to
hemodialysate in an amount similar to normal postabsorptive
values, there was not only no gain or loss of amino acids across the
dialyzer, but plasma amino acids levels did not change signifi-
cantly during the dialysis (—8 5%). When amino acids were
added to the dialysate in about three times the normal postab-
sorptive plasma concentrations, the amino acid balance during the
hemodialysis procedure was not only strongly positive but plasma
total amino acid levels rose by 45 9%.
The amount of amino acids that was taken up with the 3XAA
hemodialysis was not unexpected because of the known sieving
characteristics of the cellulose triacetate membrane and the
dialysance predicted from the membrane characteristics, the
blood and dialysate flow rates, the molecular weights of the amino
acids, and the dialysate and estimated mean plasma concentra-
tions of the amino acids. Creatinine has a molecular weight of 113,
which is close to the average molecular weight of the studied
amino acids (that is, 139 daltons). The creatinine clearance given
by the manufacturer for the CT19O G is 266 mI/mm at a blood
flow of 400 mI/mm and a dialysate flow of 500 mI/mm. Using these
values, and according to the mean of the grand total amino acid
concentrations in the predialysis and postdialysis plasma and the
grand total amino acid concentrations in the fresh dialysate, the
calculated total quantity of amino acids transferred from dialysate
to plasma should be about 39 g per treatment, a number similar to
what we obtained.
In the present study, the gain in individual amino acids with the
3XAA hemodialysis was closely correlated with the concentra-
tions of the respective amino acids in the dialysate (Fig. 2). This
finding suggests that it may be possible to accurately predict the
amino acid balance and the change in plasma amino acids
concentrations during hemodialysis from the quantity of amino
acids in the fresh dialysate and the kinetic characteristics of the
hemodialysis procedure. Thus, it may be possible to accurately
regulate the balance and postdialysis concentrations of specific
amino acids by modifying the quantity that is added to the
dialysate.
The potential benefits of hemodialytic nutrition are not well
defined, and further studies will be necessary to determine
whether it may improve the clinical status of patients. Maeda et al
added amino acids to hemodialysate and reported an increase in
plasma amino acid concentrations obtained postdialysis as com-
pared to the predialysis values [171. However, the clinical benefits
of this therapy were not clearly demonstrated. Feinstein et a! gave
amino acids and glucose by dialysis to three patients with acute or
chronic renal failure [181. Slow blood and dialysis flow rates were
employed. These authors also showed a substantial uptake of
glucose and amino acids from dialysate, but the study was not
designed to examine the effects of dialytic nutrition on clinical
outcome.
The rise of plasma amino acids with the 3XAA hemodialysis is
roughly similar to the average increase in plasma amino acids
concentrations that occurred after a meal in nondialyzed patients
with chronic renal failure that was reported by Garibotto et a!
[19]. However, in this latter study, the patients were given 4 g/kg
of ground beefsteak that provided about I g protein/kg body wt.
The greater increment in plasma amino acids per g of amino acids
absorbed in the present study probably reflects the physiological
effects of the route of administration. Thus, the amino acids in the
dialysate were transferred directly to a peripheral vein, whereas
after a meal the food remains in the stomach for up to several
hours, is slowly digested and absorbed from the intestine and most
of the organic nutrients are processed by the liver before entering
the peripheral circulation. Also, the stimulation of hormonal
secretion by these two routes of nutrient administration may be
quite different, Although these differences in the route of admin-
istration might affect the utilization of the nutrients for anabolic
or other biological processes, the finding that parenteral nutrition
provided through a systemic vein is nutritionally valuable [20]
suggests that dialytic nutrition should be beneficial as well.
In this preliminary study, we administered the amino acids in
dialysate without large amounts of carbohydrates in order to
examine the amino acid balances during hemodialysis in a more
independent fashion. In future studies, it would be of value to
examine the nutritional and metabolic effects of administering in
dialysate both amino acids and substantial amounts of other
energy sources. In particular, it could be valuable to know whether
this combined treatment will enhance the utilization of amino
acids and improve the nutritional status of malnourished mainte-
nance hemodialysis patients.
In summary, the present study suggests that substantial
amounts of amino acids may be administered to patients through
hemodialysate. These amino acids do not need to he sterilized or
administered with sterile bags, tubing or needles, and there is no
need for personnel who are trained in the preparation and the
administration of intravenous solutions (such as pharmacists).
Therefore, it may be feasible to provide these nutrients more
inexpensively in hemodialysate than by intradialytic parenteral
nutrition, even though with the 3XAA dialysate only about 26% of
the amino acids added to the dialysate were taken up by the
patient.
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